Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kiran B. Aithal"'
Autor:
Manav Korpal, Ping Zhu, Sudeep Prajapati, Guo Zhu Zheng, Nicholas Larsen, David M. Bolduc, Frédéric H. Vaillancourt, Hao Zeng, Xun Zhang, Shihua Yao, Michael J. Wick, Tarek Sahmoud, Victoria Rimkunas, Tuong-Vi Nguyen, Karthikeyan Murugesan, Alyssa D. Moriarty, Meagan Montesion, Amy Kim, Sean Irwin, Ming-Hong Hao, Lee A. Albacker, Kiran B. Aithal, Deepti Banka, Zhenhua J. Wu, Zhaojie Zhang, Xiaoling Puyang, Craig Furman
Supplementary Figure from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13142bfee94cfe0c7131be792af46c56
https://doi.org/10.1158/1535-7163.22522680
https://doi.org/10.1158/1535-7163.22522680
Autor:
Manav Korpal, Ping Zhu, Sudeep Prajapati, Guo Zhu Zheng, Nicholas Larsen, David M. Bolduc, Frédéric H. Vaillancourt, Hao Zeng, Xun Zhang, Shihua Yao, Michael J. Wick, Tarek Sahmoud, Victoria Rimkunas, Tuong-Vi Nguyen, Karthikeyan Murugesan, Alyssa D. Moriarty, Meagan Montesion, Amy Kim, Sean Irwin, Ming-Hong Hao, Lee A. Albacker, Kiran B. Aithal, Deepti Banka, Zhenhua J. Wu, Zhaojie Zhang, Xiaoling Puyang, Craig Furman
Supplementary Data from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3c5a51d03835d7dd69df06b71625f3
https://doi.org/10.1158/1535-7163.22522686.v1
https://doi.org/10.1158/1535-7163.22522686.v1
Autor:
Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua J. Wu, Deepti Banka, Kiran B. Aithal, Lee A. Albacker, Ming-Hong Hao, Sean Irwin, Amy Kim, Meagan Montesion, Alyssa D. Moriarty, Karthikeyan Murugesan, Tuong-Vi Nguyen, Victoria Rimkunas, Tarek Sahmoud, Michael J. Wick, Shihua Yao, Xun Zhang, Hao Zeng, Frédéric H. Vaillancourt, David M. Bolduc, Nicholas Larsen, Guo Zhu Zheng, Sudeep Prajapati, Ping Zhu, Manav Korpal
Publikováno v:
Molecular Cancer Therapeutics. 21:890-902
Nearly 30% of patients with relapsed breast cancer present activating mutations in estrogen receptor alpha (ERα) that confer partial resistance to existing endocrine-based therapies. We previously reported the development of H3B-5942, a covalent ER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36d847689ba41601cee0daf9b3b85720
https://doi.org/10.1158/1535-7163.mct-21-0378
https://doi.org/10.1158/1535-7163.mct-21-0378
